{"prompt": "['85% power to detect a clinically relevant treatment difference', 'from placebo of 3 points on the MADRS total score with a', 'common standard deviation of 9.0 at an overall 2-sided', 'significance level of 0.05.', 'Intra-Cellular Therapies, Inc. Confidential', 'xvii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Schematic of Study Design:', 'Visit 1', 'Total N ~525: Obtain informed consent. Screen potential patients by inclusion and', 'Screening', 'exclusion criteria; obtain history, document per Schedule of Events.', 'N - 350 Randomize', 'ITI-007 60', 'Placebo', 'N ~ 175', 'N ~ 175', 'Perform baseline assessments per Schedule of Events.', 'Visit 2', 'Dispense initial study treatment.', 'Study Day 1', 'Visits 3-8', 'Double-Blind on-treatment period.', 'Study Days', 'Perform weekly assessments per Schedule of Events.', '8 43', 'Visit 9', 'Study Day 57', 'Follow Up', 'Perform safety measures per', 'Schedule of Events.', 'Intra-Cellular Therapies, Inc. Confidential', 'xviii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['1', 'KEY ROLES AND CONTACT INFORMATION', 'Clinical Study Site', 'To be determined', 'Investigators:', 'Institutions:', 'To be determined', 'Intra-Cellular Therapies, Inc. Confidential', '1 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}